Key Highlights

  • Accenture (NYSE:ACN) rose 40.63% to USD 244.00 after October 1, 2026 results with revenue of USD 18.7 billion and record bookings of USD 84.5 billion. Hasbro (NASDAQ:HAS) rose 37.72% to USD 120.59 after October 20 results and raised guidance.
  • Charles River Laboratories (NYSE:CRL) rose 30.37% to USD 376.94 after 2030 targets and analyst upgrades, including UBS at Buy with a USD 357 target. Rubrik (NYSE:RBRK) rose 29.96% to USD 138.98 after a raised fiscal 2027 outlook and AI security launches.
  • Carnival (NYSE:CCL) rose 27.51% to USD 27.86 after a September 29 report with record net yields and falling debt, yet it is up only 0.69% in three months and down 9.22% in 2026.
  • Company reports or targets support each move, but three of the five are still recovering from earlier drops, so the gains partly reflect a low starting point. All data are as of October 28, 2026.

Accenture (NYSE:ACN): Up 40.63% After October 1 Results

Accenture (NYSE:ACN) reported results for the year ended August 31, 2026 on October 1. Fourth quarter diluted earnings were USD 3.29, up 46%, and full-year revenue was USD 74.2 billion, up 6% in dollars. Full-year diluted earnings were USD 13.56, up 12%, or USD 13.97 adjusted, up 8%. Chief executive Julie Sweet said the company exceeded its fourth quarter guidance range. Revenue above the guided range and record bookings eased fears that artificial intelligence would shrink demand for consulting work, and the shares rose sharply, a link that is inference. Consulting firms sell project work, so bookings are a leading signal and the 7% local-currency revenue growth shows demand held up in the latest quarter. For fiscal 2027 the company expects diluted earnings of USD 14.39 to USD 14.81, a rise of 6% to 9%, and revenue growth of 3% to 6% in local currency. The quarterly dividend was raised 5% to USD 1.71 a share.

Hasbro (NASDAQ:HAS): Up 37.72% on Raised Guidance

For the quarter ended September 27, 2026, Hasbro (NASDAQ:HAS) reported diluted earnings of USD 2.77, or USD 2.90 adjusted, and said results included about USD 55 million of tariff refunds. Wizards of the Coast and Digital Gaming revenue rose 31% to USD 747.2 million, led by Magic: The Gathering, up 34% to USD 616.1 million, at a 49.2% operating margin. Consumer Products revenue rose 4% to USD 827.9 million, with adjusted operating profit about double the prior year. Chief executive Chris Cocks said the quarter showed the company's strength in play. The company also owns Dungeons and Dragons and digital games within the same segment, which shifts revenue toward higher margin products. The raised outlook lifts the previous ranges of 5% to 7% revenue growth, a 25% to 26% adjusted margin and USD 1.45 billion to USD 1.50 billion of adjusted EBITDA. The company also doubled its 2026 share repurchase target. A dividend of USD 0.70 a share is payable December 2, 2026 to holders of record on November 18.

Carnival (NYSE:CCL): Up 27.51% on Record Yields

For the quarter ended August 31, Carnival (NYSE:CCL) earned adjusted USD 1.43 a share, flat year over year, despite a USD 0.10 hit from fuel and currency. Net yields beat June guidance by more than a point. Customer deposits reached a third-quarter record of USD 7.6 billion, about USD 0.5 billion above last year with flat capacity. Management said 2027 booked occupancy and pricing are at record levels and 2028 has started strongly. The fourth quarter is guided to net yields up about 1.7% and adjusted net income near USD 274 million. Cruise lines sell fixed capacity, so pricing and occupancy drive profit, and net yield measures revenue per available cruise day. Total debt fell to USD 23.9 billion at August 31 from USD 26.6 billion at November 30, 2025, and the company redeemed USD 500 million of 7% notes. S&P upgraded it to investment grade, and the company has no secured debt.

Charles River Laboratories (NYSE:CRL): Up 30.37% on 2030 Targets

Charles River Laboratories (NYSE:CRL) presented its Pathway to Purpose plan, which targets organic revenue growth of 5% to 7% a year for 2027 to 2030, a non-GAAP operating margin near 24%, low double-digit earnings growth and a cost program, Create the Future, saving more than USD 300 million. It reaffirmed 2026 earnings at the high end of USD 11.15 to USD 11.45 a share and plans to bring its non-human primate supply in house. Published coverage is dated September 24 and October 21, 2026, so the exact investor day date is not fixed here. The company supplies research models, safety testing and laboratory services to drug developers, so its revenue follows biotech funding and pharmaceutical research budgets. UBS moved to Buy from Neutral on October 21 with a USD 357 target, and RBC, Bank of America, Deutsche Bank, Jefferies, Morgan Stanley and Baird raised targets, according to published reports. Deutsche Bank had a target of USD 320 and Baird USD 334 from September 25 updates.

Rubrik (NYSE:RBRK): Up 29.96% on a Raised Outlook

For the quarter ended July 31, Rubrik (NYSE:RBRK) posted adjusted earnings of USD 0.20 a share against an adjusted loss of USD 0.03 a year earlier. Net new subscription ARR was USD 96 million, up 35%. It raised fiscal 2027 revenue guidance to USD 1.685 billion to USD 1.693 billion and adjusted earnings to USD 0.47 to USD 0.53 a share, with an ARR midpoint near USD 1.88 billion. The shares still fell more than 8% premarket the next day, so the October rise came after a period of digestion, not directly from the report. Rubrik sells software that protects and recovers data from cyberattacks, and subscription ARR is its main growth measure. October commentary pointed to analyst price target increases, expansion of Project Hourglass with Rubrik Code Guardian, the Rubrik Agent Cloud for protecting artificial intelligence agent workflows, strong large-deal expansion and a technical breakout. The wider software rebound helped: a J.P. Morgan note dated October 8 said infrastructure software had led the sector on estimate upgrades.

Where Things Stand

The answer is that company reports, raised guidance and long-term targets lifted these five. Accenture (NYSE:ACN) and Hasbro gained on strong revenue and a raised outlook. Charles River Laboratories (NYSE:CRL) gained on 2030 targets and upgrades, and it reports on November 4, 2026. Rubrik (NYSE:RBRK) gained on a raised outlook and Carnival on record yields. Several are rebounding from earlier selloffs, so valuation and the next reports will decide how much of the gain holds. The risks described above also apply to Hasbro (NASDAQ:HAS). The next company disclosures from Carnival (NYSE:CCL) are the key test. Readers can check the latest company filings for Charles River Laboratories (NYSE:CRL). This summary is not advice on Rubrik (NYSE:RBRK).